STOCK TITAN
  1. Home
  2. News
  3. TELA

TELA Bio Inc - TELA STOCK NEWS

Welcome to our dedicated news page for TELA Bio (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on TELA Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TELA Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TELA Bio's position in the market.

News
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
Rhea-AI Summary
TELA Bio, Inc. announces the U.S. commercial launch of OviTex IHR, a reinforced tissue matrix for inguinal hernia repair. The product offers trocar-compatibility for laparoscopic and robotic procedures, with three configurations available. OviTex has a strong clinical track record with low recurrence rates and high patient satisfaction. The launch aims to provide surgeons with innovative soft-tissue reconstruction solutions to enhance patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.47%
Tags
none
-
News
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
Rhea-AI Summary
TELA Bio, Inc. appoints Dr. Howard N. Langstein as Vice President of Medical Affairs and Surgeon Strategy to enhance clinical outcomes in plastic and reconstructive surgery. Dr. Langstein brings over 30 years of experience and a strong background in microvascular reconstruction and surgical innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
none
-
News
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results
Rhea-AI Summary
TELA Bio, Inc. reports strong financial results for Q4 2023 and full year 2023, with revenue reaching $17.0 million and $58.5 million, respectively. The company achieved significant growth in revenue, marking the 12th consecutive quarter and third consecutive year of at least 35% year-over-year growth. TELA Bio also saw increased demand for its OviTex® and OviTex PRS products, with revenue growth of approximately 36% and 51% for each product, respectively. Additionally, the company successfully launched LIQUIFIX FIX8™ Laparoscopic and LIQUIFIX Precision™ Open Hernia Mesh Fixation Devices in partnership with Advanced Medical Solution. TELA Bio finalized preparations for the commercial launch of OviTex IHR Reinforced Tissue Matrix in Q2 2024, contributing to the full year 2024 revenue guidance of $74.0 million to $76.0 million, reflecting a 27% to 30% year-over-year growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.1%
Tags
earnings
News
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery
Rhea-AI Summary
TELA Bio, Inc. announces the U.S. launch of LIQUIFIX FIX8™ Laparoscopic and LIQUIFIX Precision™ Open Hernia Mesh Fixation Devices, the first FDA-approved products to affix mesh without penetrating patient tissue. The devices aim to reduce risks of complications in hernia repairs by eliminating the need for mechanical tacks, sutures, or staples.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
none
-
News
TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX
Rhea-AI Summary
TELA Bio, Inc. sells distribution rights of NIVIS Fibrillar Collagen Pack to MiMedx Group, Inc. for at least $8 million. MIMEDX will pay an initial $5 million with potential future payments up to $7 million based on sales. NIVIS is a collagen matrix for wound management. TELA Bio aims to focus on expanding its hernia repair and reconstructive surgery product portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
none
-
News
TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
TELA Bio, Inc. will report its fourth quarter and full year 2023 financial results on March 21, 2024. The company focuses on soft-tissue reconstruction solutions for optimal clinical outcomes. Investors can join a conference call and webcast for more details.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
earnings
News
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
TELA Bio, Inc. approved inducement grants of restricted stock units to five new employees, covering 5,800 shares, to enhance employment compensation and retention. The grants will vest over four years, aligning with the employees' service tenure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
none
-
News
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
TELA Bio, Inc. approved inducement grants of restricted stock units covering 5,500 shares of its common stock to nine newly-hired employees. The grants were made as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio. The restricted stock units will vest in equal annual installments over four years, subject to each individual's continued service with TELA Bio through the applicable vesting dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
TELA Bio, Inc. (NASDAQ: TELA) approved inducement grants of restricted stock units covering 20,175 shares of its common stock to sixteen newly-hired employees. The restricted stock units will vest in equal annual installments over four years, subject to each individual's continued service with TELA Bio through the applicable vesting dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
TELA Bio to Take Part in Connecting the Dots
Rhea-AI Summary
TELA Bio, Inc. (NASDAQ: TELA) took part in Connecting the Dots, a series of branded films presented by MedTech Europe, including a film produced by BBC StoryWorks Commercial Productions. The series will feature a mini-documentary highlighting the use of OviTex® Reinforced Tissue Matrix in hernia repair, addressing the need for newer alternatives in hernia surgery. Surgeons perform an estimated 20 million hernia repair procedures annually, and the series aims to showcase the role of medical technologies in improving global healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.68%
Tags
none
Stock TELA logo
TELA Bio Inc

Nasdaq:TELA

TELA Rankings

#4128 Ranked by Market Cap
#4091 Ranked by Stock Gains
N/A Ranked by Dividends

TELA Stock Data

121.28M
15.79M
2.54%
86.87%
3.19%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Malvern

About TELA

tela bio, inc., a surgical reconstruction company, was created out of the desire to do things differently. combining the drive and innovation of a start-up with a seasoned medical technology team, the company aims to commercialize a portfolio of products that are purposefully designed to address a range of unmet needs in soft tissue repair. based in malvern, pennsylvania, this science-driven company is collaborating with leading surgeons to reinvigorate the soft tissue reconstruction market and bring cost-effective solutions to hospitals, surgeons and patients. please see our social media community guidelines at http://bit.ly/1uvcx0l